Article Contents ::
- 1 The Brand Name HALOTOP Has Generic Salt :: HALOBETASOL
- 2 HALOTOP Is From Company Ipca Priced :: Rs. 42
- 3 HALOTOP have HALOBETASOL is comes under Sub class #N/A of Main Class #N/A
- 4 Main Medicine Class:: #N/A Sub Medicine Class :: #N/A
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name HALOTOP Has Generic Salt :: HALOBETASOL
HALOTOP Is From Company Ipca Priced :: Rs. 42
HALOTOP have HALOBETASOL is comes under Sub class #N/A of Main Class #N/A
Main Medicine Class:: #N/A Sub Medicine Class :: #N/A
Salt Name : OR Generic Name | Form | Price : MRP /Probable | Packing | ||
HALOBETASOL | CRM | Rs. 42 | 10GM |
Brand Name | Company / Manufacturers | Strength | Unit | Price / 10GM |
HALOTOP | Ipca | 0.05%W/W | 10GM | Rs. 42 |
Company Brand Name | Salt Combination | Main Medical Class | Sub Medical Class |
From Ipca :: HALOTOP | HALOBETASOL | #N/A | #N/A |
Indications for Drugs ::
Psoriasis, Eczema, Corticosteroid-responsive dermatoses
Drug Dose ::
A thin layer should be applied to the affected skin once or twice daily, as directed by physician, and rub in gently and completely. Treatment beyond two consecutive weeks is not recommended, and the total dosage should not exceed 50 g/week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (HPA) axis. Use in children under 12 years of age is not recommended. Halobetasol Propionate Cream should not be used with occlusive dressings. As with other highly active corticosteroids, therapy should be discontinued when control has been achieved. If no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary. Use in pediatric patients Safety and effectiveness of Halobetasol Propionate cream & ointment in paediatric patients have not been established. Paediatric patients are at greater risk than adults of HPA axis suppression when they are treated with topical corticosteroids.
Contraindication ::
Halobetasol Propionate Cream/Ointment is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.
Drug Precautions ::
Systemic absorption of topical corticosteroids may cause reversible hypothalamic-pituitaryadrenal (HPA) axis suppression, manifestations of cushing’s syndrome, hyperglycemia, and glucosuria. Patients receiving large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid.
Drug Side Effects ::
The following adverse effects have been reported infrequently with topical corticosteroids. These reactions include burning, itching, dryness, folliculitis acne, hypopigmentation, perioral dermatitis, allergic contact dermatitis, skin atrophy, secondary infections, striae and miliaria.
Pregnancy category ::
3
Drug Mode of Action ::
Corticosteroids decrease inflammation by stabilizing leukocyte lysosomal membranes, preventing release of destructive acid hydrolases from leukocytes; inhibiting macrophage accumulation in inflamed areas; reducing leukocyte adhesion to capillary endothelium; reducing capillary wall permeability and edema formation; decreasing complement components; antagonizing histamine activity and release of kinin from substrates; reducing fibroblast proliferation, collagen deposition, and subsequent scar tissue formation.
Drug Interactions ::
0